Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area when it won approval with partner CRISPR Therapeutics for a gene editing therapy for blood disorders.
Next, Vertex is about to show that it can conquer one of the world's most common health problems: pain. The company recently reported positive phase 3 data for VX-548, its treatment candidate for moderate-to-severe acute pain, and aims to request regulatory approval by the middle of this year.
At this exciting time, is Vertex stock a buy?
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€456.30
1.110%
The stock is one of the favorites of our community with 55 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 450 € is below the current price of 456.3 € for Vertex Pharmaceuticals Inc., so the potential is actually -1.38%.
